162 related articles for article (PubMed ID: 29365125)
21. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
[TBL] [Abstract][Full Text] [Related]
22. A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Mussini C; Roncaglia E; Borghi V; Rusconi S; Nozza S; Cattelan AM; Segala D; Bonfanti P; Di Biagio A; Barchi E; Focà E; Degli Antoni A; Bonora S; Francisci D; Limonta S; Antinori A; D'Ettorre G; Maggiolo F
PLoS One; 2019; 14(9):e0222650. PubMed ID: 31560700
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
[TBL] [Abstract][Full Text] [Related]
25. Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
Yamada E; Takagi R; Tanabe Y; Fujiwara H; Hasegawa N; Kato S
Int J Clin Pharmacol Ther; 2017 Jul; 55(7):567-570. PubMed ID: 28427498
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Jackson A; Moyle G; Dickinson L; Back D; Khoo S; Taylor J; Gedela K; Abongomera G; Gazzard B; Boffito M
Antivir Ther; 2012; 17(1):19-24. PubMed ID: 22267465
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
Mora-Peris B; Croucher A; Else LJ; Vera JH; Khoo S; Scullard G; Back D; Winston A
J Antimicrob Chemother; 2013 Jun; 68(6):1348-53. PubMed ID: 23364475
[TBL] [Abstract][Full Text] [Related]
28. Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
MacBrayne CE; Blum JD; Kiser JJ
Ann Pharmacother; 2014 Jun; 48(6):816-9. PubMed ID: 24615629
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
30. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Rossetti B; Gagliardini R; Meini G; Sterrantino G; Colangeli V; Re MC; Latini A; Colafigli M; Vignale F; Rusconi S; Micheli V; Di Biagio A; Orofino G; Ghisetti V; Fantauzzi A; Vullo V; Grima P; Francisci D; Mastroianni C; Antinori A; Trezzi M; Lisi L; Navarra P; Canovari B; D'Arminio Monforte A; Lamonica S; D'Avino A; Zazzi M; Di Giambenedetto S; De Luca A;
PLoS One; 2017; 12(11):e0187393. PubMed ID: 29161288
[TBL] [Abstract][Full Text] [Related]
31. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
[TBL] [Abstract][Full Text] [Related]
32. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
[TBL] [Abstract][Full Text] [Related]
34. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.
Spinner CD; Kümmerle T; Krznaric I; Degen O; Schwerdtfeger C; Zink A; Wolf E; Klinker HHF; Boesecke C
J Antimicrob Chemother; 2017 Sep; 72(9):2679-2681. PubMed ID: 28859438
[No Abstract] [Full Text] [Related]
39. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
Ter Heine R; Mulder JW; van Gorp EC; Wagenaar JF; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2010 May; 69(5):475-83. PubMed ID: 20573083
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Tolerability of Integrase Inhibitors in Antiretroviral-Naive Patients.
D'Abbraccio M; Busto A; De Marco M; Figoni M; Maddaloni A; Abrescia N
AIDS Rev; 2015; 17(3):171-85. PubMed ID: 26450805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
